Poolbeg Pharma held a Capital Markets Day in London on 30 November. Amongst several presentations from the company and from leading experts, Poolbeg stressed its infectious diseases capabilities both in the discovery and development of small molecule anti-viral drugs (initially in influenza and Respiratory Syncytial Virus, RSV) and anti-bacterial vaccines, its proprietary patient datasets that aid these drug discovery programmes and its business development strategy. The Group noted again that i ....
